The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease

AIM: Pridopidine, a new oral drug for treatment of patients with motor symptoms associated with Huntington's Disease (HD) is currently under development. In steady‐state conditions, pridopidine elimination is mediated primarily through renal excretion. This study evaluated single dose and stead...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabinovich‐Guilatt, L., Siegler, K. E., Schultz, A., Halabi, A., Rembratt, A., Spiegelstein, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833154/
https://www.ncbi.nlm.nih.gov/pubmed/26407011
http://dx.doi.org/10.1111/bcp.12792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833154/
https://www.ncbi.nlm.nih.gov/pubmed/26407011
http://dx.doi.org/10.1111/bcp.12792

Ejemplares similares